Prostatic Neoplasms Clinical Trials
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED
N
Active, not recruiting
- Prostatic Neoplasms
- Bethesda, MarylandNational Institutes of Health Clinical Center
2022-04-07
Apr 7, 2022M
Recruiting
- Prostatic Neoplasms
- Pembrolizumab
- +2 more
- Mobile, Alabama
- +257 more
2022-04-07
Apr 7, 2022N
Recruiting
- Prostatic Neoplasms
- Bethesda, MarylandNational Institutes of Health Clinical Center
2022-04-07
Apr 7, 2022N
Enrolling by invitation
- Metastatic Prostate Cancer
- +4 more
- 18F-NaF
- +2 more
- Bethesda, MarylandNational Institutes of Health Clinical Center
2022-04-07
Apr 7, 2022N
Recruiting
- Prostatic Neoplasms
- Bethesda, MarylandNational Institutes of Health Clinical Center
2022-04-07
Apr 7, 2022N
Completed
- Prostatic Neoplasms
- +4 more
- ME TARP vaccine
- Bethesda, MarylandNational Institutes of Health Clinical Center, 9000 Rockville Pi
2022-04-07
Apr 7, 2022N
Recruiting
- Cancer Of Prostate
- +4 more
- Bethesda, MarylandNational Institutes of Health Clinical Center, 9000 Rockville Pi
2022-04-07
Apr 7, 2022I
Recruiting
- Prostatic Neoplasms
- Biopsy & Imaging
- Coventry, United Kingdom
- +5 more
2022-03-29
Mar 29, 2022M
Recruiting
- Prostatic Neoplasms
- Pembrolizumab
- +4 more
- Hefei, Anhui, China
- +19 more
2022-04-06
Apr 6, 2022E
Not yet recruiting
- Prostatic Neoplasms
- +16 more
- Abemaciclib
- +3 more
- Birmingham, Alabama
- +233 more
2022-03-28
Mar 28, 2022R
Recruiting
- Prostatic Neoplasms
- Gallium-68 citrate PET
- Positron Emission Tomography (PET)
- San Francisco, CaliforniaUniversity of California, San Francisco
2022-03-28
Mar 28, 2022F
Recruiting
- Prostatic Neoplasms
- Positron emission tomography/computerized tomography (PET/CT)
- Xi'an, Shaanxi, ChinaFirst Affiliate Hospital of Xi'an Jiaotong University
2022-03-23
Mar 23, 2022N
Recruiting
- Prostatic Neoplasms
- Prostate Cancer
- Bethesda, MarylandNational Institutes of Health Clinical Center, 9000 Rockville Pi
2022-03-31
Mar 31, 2022M
Active, not recruiting
- Prostatic Neoplasms
- Pembrolizumab
- +4 more
- Fullerton, California
- +192 more
2022-03-30
Mar 30, 2022B
ODM-201 in Addition to Standard ADT and Docetaxel in Metastatic Castration Sensitive Prostate Cancer
Active, not recruiting
- Prostatic Neoplasms
- BAY1841788 / darolutamide (ODM-201)
- +3 more
- Chandler, Arizona
- +298 more
2022-03-30
Mar 30, 2022B
Recruiting
- Prostatic Neoplasms
- Radium-223 dichloride (Xofigo, BAY88-8223)
- Multiple Locations, JapanMany Locations
2022-03-29
Mar 29, 2022V
Recruiting
- Urinary Bladder Neoplasms
- +2 more
- Self-reported lymphedema
- +2 more
- Göteborg, SwedenSahlgrenska University Hospital
2022-03-16
Mar 16, 2022O
Recruiting
- Prostatic Neoplasms
- Prostatectomy/Surgery
- Radiotherapy with adjuvant androgen deprivation therapy
- Aalborg, Denmark
- +29 more
2022-03-30
Mar 30, 2022A
Available
- Prostatic Neoplasms
- Apalutamide
- ADT (Standard of Care)
- Florianopolis, Brazil
- +19 more
2022-03-28
Mar 28, 2022H
Enrolling by invitation
- Prostatic Neoplasms
- multiparametric MRI Diagnostics
- Herlev, DenmarkDepartment of Urology, Herlev University Hospital Herlev
2022-03-25
Mar 25, 2022A
Active, not recruiting
- Prostatic Neoplasms
- Apalutamide
- +3 more
- Phoenix, Arizona
- +183 more
2022-03-24
Mar 24, 2022A
Active, not recruiting
- Prostatic Neoplasms
- Apalutamide
- Placebo
- Birmingham, Alabama
- +390 more
2022-03-24
Mar 24, 2022J
Active, not recruiting
- Prostatic Neoplasms
- Beijing, China
- +3 more
2022-03-24
Mar 24, 2022J
J
Recruiting
- Prostatic Neoplasms
- Adenocarcinoma
- Duarte, California
- +6 more
2022-03-24
Mar 24, 2022